These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 33006900)
21. Transformations, Lineage Comparisons, and Analysis of Down-to-Up Protomer States of Variants of the SARS-CoV-2 Prefusion Spike Protein, Including the UK Variant B.1.1.7. Peters MH; Bastidas O; Kokron DS; Henze CE Microbiol Spectr; 2021 Sep; 9(1):e0003021. PubMed ID: 34346753 [TBL] [Abstract][Full Text] [Related]
22. Exploring Conformational Landscapes and Cryptic Binding Pockets in Distinct Functional States of the SARS-CoV-2 Omicron BA.1 and BA.2 Trimers: Mutation-Induced Modulation of Protein Dynamics and Network-Guided Prediction of Variant-Specific Allosteric Binding Sites. Verkhivker G; Alshahrani M; Gupta G Viruses; 2023 Sep; 15(10):. PubMed ID: 37896786 [TBL] [Abstract][Full Text] [Related]
23. Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein. Behloul N; Baha S; Shi R; Meng J Virus Res; 2020 Sep; 286():198058. PubMed ID: 32531235 [TBL] [Abstract][Full Text] [Related]
24. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms. Ali A; Vijayan R Sci Rep; 2020 Aug; 10(1):14214. PubMed ID: 32848162 [TBL] [Abstract][Full Text] [Related]
25. Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveals the Allosteric Duality of Functionally Adaptable Hotspots. Verkhivker G; Agajanian S; Oztas D; Gupta G J Chem Theory Comput; 2021 Jul; 17(7):4578-4598. PubMed ID: 34138559 [TBL] [Abstract][Full Text] [Related]
26. Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2. Martin WR; Cheng F J Proteome Res; 2020 Nov; 19(11):4670-4677. PubMed ID: 32907334 [TBL] [Abstract][Full Text] [Related]
27. Integrating Conformational Dynamics and Perturbation-Based Network Modeling for Mutational Profiling of Binding and Allostery in the SARS-CoV-2 Spike Variant Complexes with Antibodies: Balancing Local and Global Determinants of Mutational Escape Mechanisms. Verkhivker G; Agajanian S; Kassab R; Krishnan K Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883520 [TBL] [Abstract][Full Text] [Related]
28. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Vankadari N; Wilce JA Emerg Microbes Infect; 2020; 9(1):601-604. PubMed ID: 32178593 [TBL] [Abstract][Full Text] [Related]
30. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Kim SY; Jin W; Sood A; Montgomery DW; Grant OC; Fuster MM; Fu L; Dordick JS; Woods RJ; Zhang F; Linhardt RJ Antiviral Res; 2020 Sep; 181():104873. PubMed ID: 32653452 [TBL] [Abstract][Full Text] [Related]
31. AlphaFold2 Predictions of Conformational Ensembles and Atomistic Simulations of the SARS-CoV-2 Spike XBB Lineages Reveal Epistatic Couplings between Convergent Mutational Hotspots that Control ACE2 Affinity. Raisinghani N; Alshahrani M; Gupta G; Xiao S; Tao P; Verkhivker G J Phys Chem B; 2024 May; 128(19):4696-4715. PubMed ID: 38696745 [TBL] [Abstract][Full Text] [Related]
32. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor. Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122 [TBL] [Abstract][Full Text] [Related]
33. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance. Robson B Comput Biol Med; 2020 Jun; 121():103749. PubMed ID: 32568687 [TBL] [Abstract][Full Text] [Related]
34. Allosteric pathways of SARS and SARS-CoV-2 spike protein identified by neural relational inference. Hu Y; Li M; Wang Q Proteins; 2024 Jul; 92(7):865-873. PubMed ID: 38459426 [TBL] [Abstract][Full Text] [Related]
35. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306 [TBL] [Abstract][Full Text] [Related]
36. In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins. Maffucci I; Contini A J Proteome Res; 2020 Nov; 19(11):4637-4648. PubMed ID: 32893632 [TBL] [Abstract][Full Text] [Related]
37. Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method. Lim H; Baek A; Kim J; Kim MS; Liu J; Nam KY; Yoon J; No KT Sci Rep; 2020 Oct; 10(1):16862. PubMed ID: 33033344 [TBL] [Abstract][Full Text] [Related]
39. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2. Basu A; Sarkar A; Maulik U Sci Rep; 2020 Oct; 10(1):17699. PubMed ID: 33077836 [TBL] [Abstract][Full Text] [Related]
40. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]